Pretreatment PSA Velocity as a Predictor of Disease Outcome Following Radical Radiation Therapy

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 5, 2007, Pages 1425-1429

  Palma, David ^a   Tyldesley, Scott ^a   Blood, Paul ^a   Liu, Mitchell ^a   Morris, James ^a   Pickles, Tom ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Prostate cancer; Prostate specific antigen; Prostate specific antigen velocity; Radiotherapy

Indexed keywords

ANTIGENS; HORMONES; PATIENT TREATMENT; RADIOTHERAPY; REGRESSION ANALYSIS; TUMORS;

PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; PROSTATE-SPECIFIC ANTIGEN VELOCITY;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RECURRENCE; REGRESSION ANALYSIS;

EID: 33947541761     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.11.006     Document Type: Article

References (9)

1. Lukka H., Warde P., Pickles T., et al. Controversies in prostate cancer radiotherapy: Consensus development. Can J Urol 8 (2001) 1314-1322
2. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
3. Sengupta S., Myers R.P., Slezak J.M., et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
4. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
5. Pollack A. Is pretreatment PSA velocity associated with prostate-cancer-specific mortality rate after radiotherapy?. Nat Clin Practice Urol 3 (2006) 12-13
6. D'Amico A.V., Loffredo M., Renshaw A.A., et al. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 24 (2006) 4190-4195
7. Goluboff E.T., Heitjan D.F., DeVries G.M., et al. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol 158 (1997) 1876-1879
8. Pickles T., Kim-Sing C., Morris W.J., et al. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57 (2003) 11-18
9. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974